Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00141089 |
Tegaserod (HTF919) is an aminoguanidine indole compound and a member of a class of subgroup-selective 5-hydroxytryptamine (5-HT) agonists.
The aim of this study was to evaluate the efficacy and safety of tegaserod on bowel habits in male patients with chronic constipation.
Condition | Intervention | Phase |
---|---|---|
Chronic Constipation |
Drug: Tegaserod |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation. |
Estimated Enrollment: | 1026 |
Study Start Date: | March 2004 |
Study Completion Date: | February 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Study ID Numbers: | CHTF919E2309 |
Study First Received: | August 31, 2005 |
Last Updated: | January 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00141089 |
Health Authority: | United States: Institutional Review Board |
Male patients, chronic constipation, tegaserod |
Signs and Symptoms Signs and Symptoms, Digestive Constipation Serotonin Tegaserod |
Serotonin Agonists Neurotransmitter Agents Serotonin Agents |
Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Pharmacologic Actions |